HRP20120105T1 - Aminoheterociklički spojevi - Google Patents

Aminoheterociklički spojevi Download PDF

Info

Publication number: HRP20120105T1
Authority: HR; Croatia
Prior art keywords: methyl; pyrazolo; dihydro; pyrimidin; tetrahydro
Prior art date: 2007-05-11

Application number

HR20120105T

Other languages

English (en)

Croatian (hr)

Inventor

Robert Verhoest Patrick

Proulx-Lafrance Caroline

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-11

Filing date

2008-05-05

Publication date

2012-02-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39672073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120105(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-05 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2012-02-29 Publication of HRP20120105T1 publication Critical patent/HRP20120105T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Virology (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

HR20120105T 2007-05-11 2008-05-05 Aminoheterociklički spojevi HRP20120105T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91733307P	2007-05-11	2007-05-11
PCT/IB2008/001125 WO2008139293A1 (en)	2007-05-11	2008-05-05	Amino-heterocyclic compounds

Publications (1)

Publication Number	Publication Date
HRP20120105T1 true HRP20120105T1 (hr)	2012-02-29

Family

ID=39672073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20120105T HRP20120105T1 (hr)	2007-05-11	2008-05-05	Aminoheterociklički spojevi

Country Status (43)

Country	Link
US (1)	US7964607B2 (da)
EP (1)	EP2152712B1 (da)
JP (1)	JP4579346B2 (da)
KR (1)	KR101222330B1 (da)
CN (1)	CN101687876B (da)
AP (1)	AP2524A (da)
AR (1)	AR066502A1 (da)
AT (1)	ATE540954T1 (da)
AU (1)	AU2008249750B2 (da)
BR (1)	BRPI0811280B8 (da)
CA (1)	CA2687035C (da)
CL (1)	CL2008001374A1 (da)
CO (1)	CO6241157A2 (da)
CR (1)	CR11095A (da)
CU (1)	CU23834B1 (da)
CY (1)	CY1112332T1 (da)
DK (1)	DK2152712T3 (da)
DO (1)	DOP2009000258A (da)
EA (1)	EA016510B1 (da)
EC (1)	ECSP099728A (da)
ES (1)	ES2377849T3 (da)
GE (1)	GEP20125405B (da)
GT (1)	GT200900294A (da)
HR (1)	HRP20120105T1 (da)
IL (1)	IL201977A (da)
MA (1)	MA31373B1 (da)
ME (1)	ME00954B (da)
MX (1)	MX2009011830A (da)
MY (1)	MY147330A (da)
NI (1)	NI200900204A (da)
NZ (1)	NZ580904A (da)
PA (1)	PA8779901A1 (da)
PE (1)	PE20090247A1 (da)
PL (1)	PL2152712T3 (da)
PT (1)	PT2152712E (da)
RS (1)	RS52166B (da)
SI (1)	SI2152712T1 (da)
SV (1)	SV2009003411A (da)
TN (1)	TN2009000471A1 (da)
TW (1)	TWI362262B (da)
UA (1)	UA94660C2 (da)
WO (1)	WO2008139293A1 (da)
ZA (1)	ZA200907776B (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
JP5498392B2 (ja)	2007-11-30	2014-05-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR20110063447A (ko)	2008-09-08	2011-06-10	베링거 인겔하임 인터내셔날 게엠베하	피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
LT2889033T (lt)	2008-11-19	2018-07-10	Forum Pharmaceuticals Inc.	Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
TWI404721B (zh)	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
PT2414363E (pt)	2009-03-31	2014-02-26	Boehringer Ingelheim Int	Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
JP5808319B2 (ja) *	2009-05-11	2015-11-10	フォルムファーマシューティカルズ、インコーポレイテッド	アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
JP2012526810A (ja)	2009-05-13	2012-11-01	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
WO2011043816A1 (en) *	2009-10-08	2011-04-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
PE20170923A1 (es)	2010-05-17	2017-07-12	Forum Pharmaceuticals Inc	Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
EP2603511B1 (en)	2010-08-12	2017-03-15	Boehringer Ingelheim International GmbH	6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
RS54834B1 (sr)	2010-09-07	2016-10-31	Astellas Pharma Inc	Jedinjenja pirazolokvinolina
EP2619208B1 (en)	2010-09-20	2016-11-09	Ironwood Pharmaceuticals, Inc.	Imidazotriazinone compounds
US20130040971A1 (en) *	2011-02-14	2013-02-14	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
JO3116B1 (ar)	2011-10-07	2017-09-20	Eisai R&D Man Co Ltd	مشتق بيرازولوكينولين كمثبطات ل pde9
BR112015007731B1 (pt) *	2011-10-10	2022-05-31	H. Lundbeck A/S	Composto, composição farmacêutica que o compreende e uso do mesmo
BR112014018199A8 (pt)	2012-01-26	2021-03-02	H Lundbeck As	inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
HK1206726A1 (en)	2012-03-19	2016-01-15	Ironwood Pharmaceuticals, Inc.	Imidazotriazinone compounds
EP3461481A1 (en)	2012-05-08	2019-04-03	Forum Pharmaceuticals Inc.	Methods of maintaining, treating or improving cognitive function
EP2867236B1 (en)	2012-06-29	2017-06-14	Pfizer Inc	Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014024125A1 (en)	2012-08-08	2014-02-13	Celon Pharma S.A.	Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US9801882B2 (en)	2013-02-17	2017-10-31	Intra-Cellular Therapies, Inc.	Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9573947B2 (en)	2013-04-05	2017-02-21	Eisai R&D Management Co., Ltd.	Salt of pyrazoloquinoline derivative, and crystal thereof
JP6244353B2 (ja)	2013-04-05	2017-12-06	エーザイ・アール・アンド・ディー・マネジメント株式会社	ピリジニルピラゾロキノリン化合物
CN103626774B (zh) *	2013-11-20	2015-11-04	苏州明锐医药科技有限公司	伊鲁替尼的制备方法
EP3083618B1 (en)	2013-12-17	2018-02-21	Pfizer Inc	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
CA2961212C (en) *	2014-09-17	2024-02-06	Intra-Cellular Therapies, Inc.	Compounds and methods
TW201629064A (zh)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	作爲ｐｄｅ１抑制劑之三唑並吡酮
HK1244427A1 (zh) *	2014-12-06	2018-08-10	Intra-Cellular Therapies, Inc.	有机化合物
CA2969594A1 (en)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Pde2 inhibiting organic compounds
EP3237401B1 (en)	2014-12-22	2019-03-06	Pfizer Inc	Antagonists of prostaglandin ep3 receptor
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
PT3865484T (pt)	2015-07-07	2024-01-30	H Lundbeck As	Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
RU2722149C1 (ru)	2015-09-14	2020-05-27	Пфайзер Инк.	Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
JP6983161B2 (ja)	2015-09-15	2021-12-17	プラクシス・バイオリサーチ・エルエルシー	フェンカンファミンのプロドラッグ
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN105669680B (zh) *	2016-03-24	2018-02-23	南京药捷安康生物科技有限公司	吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
TWI729109B (zh)	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
MX2018016127A (es)	2016-07-06	2019-05-30	Imara Inc	Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
WO2018073251A1 (en)	2016-10-18	2018-04-26	H. Lundbeck A/S	Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
AU2017350473A1 (en)	2016-10-28	2019-04-18	H. Lundbeck A/S	Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018078042A1 (en)	2016-10-28	2018-05-03	H. Lundbeck A/S	Combination treatments comprising administration of imidazopyrazinones
KR102590848B1 (ko)	2016-12-28	2023-10-19	다트 뉴로사이언스, 엘엘씨	Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
CN115746003B (zh) *	2017-05-26	2024-08-09	卡都瑞恩医药公司	制备和使用pde9抑制剂的方法
KR20200010211A (ko)	2017-06-01	2020-01-30	에자이 알앤드디 매니지먼트 가부시키가이샤	Pde9 저해제를 포함하는 약제학적 조성물
SG10202113199RA (en)	2017-06-01	2021-12-30	Eisai R&D Man Co Ltd	Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
RU2019135834A (ru)	2017-06-01	2021-07-13	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
KR20200010220A (ko)	2017-06-01	2020-01-30	에자이 알앤드디 매니지먼트 가부시키가이샤	피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
AU2018281131B2 (en)	2017-06-08	2022-01-20	Merck Sharp & Dohme Corp.	Pyrazolopyrimidine PDE9 inhibitors
DK3717488T3 (da)	2017-11-27	2021-12-13	Dart Neuroscience Llc	Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
CN110357888A (zh) *	2018-04-09	2019-10-22	南京药捷安康生物科技有限公司	杂环磷酸二酯酶抑制剂及其用途
CA3100988A1 (en)	2018-05-25	2019-11-28	Imara Inc.	Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en)	2018-08-31	2020-03-05	Imara Inc.	Pde9 inhibitors for treating sickle cell disease
US12194042B2 (en)	2018-10-21	2025-01-14	Intra-Cellular Therapies, Inc.	Uses
KR102706457B1 (ko) *	2018-12-06	2024-09-11	한국화학연구원	Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CN111471059B (zh)	2019-01-23	2022-12-02	药捷安康(南京)科技股份有限公司	Pde9抑制剂及其用途
US12144815B2 (en)	2021-02-23	2024-11-19	Hoth Therapeutics, Inc.	Use of aprepitant for treating Alzheimer's disease
US12012412B2 (en) *	2021-12-16	2024-06-18	Pfizer Inc.	Solid forms of pyrazolo[3,4-d]pyrimidine compounds
IL314895A (en) *	2022-02-16	2024-10-01	Duke Street Bio Ltd	Pharmaceutical compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020156277A1 (en)	2001-04-20	2002-10-24	Fick David B.	Synthesis and methods of use of purine analogues and derivatives
EP1396488A1 (en)	2001-05-23	2004-03-10	Mitsubishi Pharma Corporation	Fused heterocyclic compound and medicinal use thereof
JP2005508978A (ja) *	2001-11-02	2005-04-07	ファイザー・プロダクツ・インク	Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
HN2002000317A (es) *	2001-11-02	2003-05-21	Pfizer	Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
AU2003253915A1 (en) *	2002-07-12	2004-02-02	Massachusetts Institute Of Technology	Reconfigurable microphotonics devices via deformable membrane platform
DE10238722A1 (de) *	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
US7051174B2 (en) *	2002-09-24	2006-05-23	International Business Machines Corporation	Method, system, and program for restoring data in cache
WO2004037176A2 (en)	2002-10-21	2004-05-06	Bristol-Myers Squibb Company	Quinazolinones and derivatives thereof as factor xa inhibitors
US7111287B2 (en) *	2003-01-10	2006-09-19	International Business Machines Corporation	Global processor resource assignment in an assembler
DE602004007840T2 (de)	2003-03-18	2008-04-10	The Jordanian Pharmaceutical Manufacturing Co. Ltd.	Pyrazolopyrimidinon und ihre Verwendung als PDE-Inhibitoren
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DE10320785A1 (de) *	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine

2008
- 2008-05-05 RS RS20120094A patent/RS52166B/sr unknown
- 2008-05-05 AP AP2009005048A patent/AP2524A/xx active
- 2008-05-05 PT PT08737600T patent/PT2152712E/pt unknown
- 2008-05-05 HR HR20120105T patent/HRP20120105T1/hr unknown
- 2008-05-05 MX MX2009011830A patent/MX2009011830A/es active IP Right Grant
- 2008-05-05 DK DK08737600.0T patent/DK2152712T3/da active
- 2008-05-05 ME MEP-2009-330A patent/ME00954B/me unknown
- 2008-05-05 AT AT08737600T patent/ATE540954T1/de active
- 2008-05-05 CA CA2687035A patent/CA2687035C/en active Active
- 2008-05-05 ES ES08737600T patent/ES2377849T3/es active Active
- 2008-05-05 CN CN2008800242732A patent/CN101687876B/zh active Active
- 2008-05-05 PL PL08737600T patent/PL2152712T3/pl unknown
- 2008-05-05 EA EA200901373A patent/EA016510B1/ru unknown
- 2008-05-05 WO PCT/IB2008/001125 patent/WO2008139293A1/en not_active Ceased
- 2008-05-05 GE GEAP200811556A patent/GEP20125405B/en unknown
- 2008-05-05 MY MYPI20094735A patent/MY147330A/en unknown
- 2008-05-05 UA UAA200911482A patent/UA94660C2/ru unknown
- 2008-05-05 KR KR1020097025802A patent/KR101222330B1/ko active Active
- 2008-05-05 SI SI200830543T patent/SI2152712T1/sl unknown
- 2008-05-05 NZ NZ580904A patent/NZ580904A/en unknown
- 2008-05-05 AU AU2008249750A patent/AU2008249750B2/en active Active
- 2008-05-05 JP JP2010507997A patent/JP4579346B2/ja active Active
- 2008-05-05 BR BRPI0811280A patent/BRPI0811280B8/pt active IP Right Grant
- 2008-05-05 EP EP08737600A patent/EP2152712B1/en active Active
- 2008-05-08 PE PE2008000812A patent/PE20090247A1/es active IP Right Grant
- 2008-05-09 US US12/118,062 patent/US7964607B2/en active Active
- 2008-05-09 CL CL2008001374A patent/CL2008001374A1/es unknown
- 2008-05-09 TW TW097117227A patent/TWI362262B/zh active
- 2008-05-09 PA PA20088779901A patent/PA8779901A1/es unknown
- 2008-05-09 AR ARP080101964A patent/AR066502A1/es active IP Right Grant
2009
- 2009-11-05 IL IL201977A patent/IL201977A/en not_active IP Right Cessation
- 2009-11-05 CR CR11095A patent/CR11095A/es unknown
- 2009-11-05 ZA ZA2009/07776A patent/ZA200907776B/en unknown
- 2009-11-06 CU CU2009000184A patent/CU23834B1/es active IP Right Grant
- 2009-11-06 TN TNP2009000471A patent/TN2009000471A1/fr unknown
- 2009-11-09 NI NI200900204A patent/NI200900204A/es unknown
- 2009-11-10 GT GT200900294A patent/GT200900294A/es unknown
- 2009-11-10 CO CO09127785A patent/CO6241157A2/es active IP Right Grant
- 2009-11-10 EC EC2009009728A patent/ECSP099728A/es unknown
- 2009-11-10 DO DO2009000258A patent/DOP2009000258A/es unknown
- 2009-11-11 SV SV2009003411A patent/SV2009003411A/es unknown
- 2009-11-11 MA MA32341A patent/MA31373B1/fr unknown
2012
- 2012-02-06 CY CY20121100125T patent/CY1112332T1/el unknown

Also Published As

Publication number	Publication date
AP2524A (en)	2012-12-04
NI200900204A (es)	2010-03-11
RS52166B (sr)	2012-08-31
DK2152712T3 (da)	2012-03-26
ECSP099728A (es)	2009-12-28
AR066502A1 (es)	2009-08-26
SV2009003411A (es)	2010-05-21
ES2377849T3 (es)	2012-04-02
EP2152712B1 (en)	2012-01-11
CA2687035C (en)	2011-09-20
ZA200907776B (en)	2011-01-26
IL201977A (en)	2014-07-31
PT2152712E (pt)	2012-02-29
PA8779901A1 (es)	2008-12-18
EA016510B1 (ru)	2012-05-30
TWI362262B (en)	2012-04-21
GT200900294A (es)	2011-08-29
MY147330A (en)	2012-11-30
US7964607B2 (en)	2011-06-21
EA200901373A1 (ru)	2010-06-30
ME00954B (me)	2012-06-20
KR20100007985A (ko)	2010-01-22
CU20090184A7 (es)	2011-07-11
JP4579346B2 (ja)	2010-11-10
CR11095A (es)	2009-12-04
JP2010526863A (ja)	2010-08-05
PE20090247A1 (es)	2009-03-13
TN2009000471A1 (fr)	2011-03-31
AU2008249750A1 (en)	2008-11-20
KR101222330B1 (ko)	2013-01-15
TW200902015A (en)	2009-01-16
BRPI0811280B8 (pt)	2021-05-25
UA94660C2 (en)	2011-05-25
AU2008249750B2 (en)	2011-07-14
HK1142595A1 (en)	2010-12-10
BRPI0811280A2 (pt)	2015-01-20
CL2008001374A1 (es)	2008-11-14
PL2152712T3 (pl)	2012-05-31
DOP2009000258A (es)	2010-05-15
AP2009005048A0 (en)	2009-12-31
MX2009011830A (es)	2009-11-13
ATE540954T1 (de)	2012-01-15
CU23834B1 (es)	2012-10-15
US20090030003A1 (en)	2009-01-29
NZ580904A (en)	2012-02-24
MA31373B1 (fr)	2010-05-03
BRPI0811280B1 (pt)	2021-05-11
CA2687035A1 (en)	2008-11-20
IL201977A0 (en)	2010-06-16
GEP20125405B (en)	2012-02-27
EP2152712A1 (en)	2010-02-17
CN101687876B (zh)	2012-12-12
CO6241157A2 (es)	2011-01-20
SI2152712T1 (sl)	2012-03-30
WO2008139293A1 (en)	2008-11-20
CY1112332T1 (el)	2015-12-09
CN101687876A (zh)	2010-03-31

Publication	Publication Date	Title
HRP20120105T1 (hr)	2012-02-29	Aminoheterociklički spojevi
RU2473549C2 (ru)	2013-01-27	Пиримидиновые соединения, композиции и способы применения
JP2021518395A5 (da)	2021-09-09
JP7654071B2 (ja)	2025-03-31	複素環スピロ化合物及び使用方法
AU2019240299B2 (en)	2023-06-22	SHP2 phosphatase inhibitors and methods of use thereof
JP2021519318A5 (da)	2022-03-31
JP2021519291A5 (da)	2022-03-30
RU2020133727A (ru)	2022-04-21	Ингибиторы shp2 и их применение
JP2014506929A5 (da)	2015-04-16
JP2015504057A5 (da)	2016-02-12
JP2016504363A5 (da)	2017-01-12
AU2017277732A1 (en)	2018-12-20	New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
JP2019535664A5 (da)	2020-10-15
RU2014102962A (ru)	2015-08-10	Новые соединения-ингибиторы фосфодиэстеразы типа 10а
JP2017530960A5 (da)	2018-11-08
JP2016500671A5 (da)	2016-11-17
JP2021504380A5 (da)	2021-12-16
JP2015537010A5 (da)	2016-12-22
JP2013500975A5 (da)	2013-08-08
JP2020522570A5 (da)	2021-07-26
JP2021503004A5 (da)	2021-12-16
RU2016140338A (ru)	2018-04-19	Азаспиро производные в качестве антагонистов trpm8
JP2021506941A5 (da)	2022-01-06
WO2022093856A1 (en)	2022-05-05	Heterocyclic spiro compounds and methods of use
RU2015122895A (ru)	2017-01-10	Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта